Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Apellis Pharmaceuticals Inc (APLS)  
$29.85 0.74 (2.42%) as of 4:30 Thu 9/26


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 114,470,000
Market Cap: 3.42(B)
Last Volume: 0 Avg Vol: 0
52 Week Range: $33.59 - $72.47
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

            6 Months   1 Year   2 Year  
 
Company Profile   Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of therapeutic compounds to treat disease through the inhibition of the complement system at the level of C3. Co.'s primary product candidate, pegcetacoplan, is a conjugate of a compstatin analogue, formulated both for intravitreal administration by injections directly into the eye, and systemic administration by subcutaneous injection, which is an injection into the tissue under the skin. Co. is also developing APL-9 for the prevention of complement immune system activation coincident with adeno-associated virus vector administration for gene therapies and other indications.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 37,742 226,756 922,476 1,381,800
Total Sell Value $1,369,269 $10,141,197 $52,729,860 $84,059,185
Total People Sold 2 4 14 15
Total Sell Transactions 3 7 72 131
End Date 2024-06-27 2024-03-26 2023-09-26 2022-09-26

   
Records found: 717
  Page 17 of 29  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2022-02-10 4 D $47.12 $41,230 D/D (875) 103,403     -
   Grossi Federico CHIEF MEDICAL OFFICER   •       •      –    2022-02-10 4 D $47.12 $33,220 D/D (705) 102,861     -
   Townsend Adam J. Chief Commercial Officer   •       •      –    2022-02-10 4 D $47.12 $42,172 D/D (895) 44,013     -
   Delong Mark Jeffrey Senior Vice President   •       •      –    2022-02-10 4 A $0.00 $0 D/D 4,901 28,481     -
   Delong Mark Jeffrey Senior Vice President   •       •      –    2022-02-10 4 D $47.12 $12,770 D/D (271) 23,580     -
   Francois Cedric Chief Executive Officer   •       •      –    2022-02-10 4 D $47.12 $118,884 D/D (2,523) 955,940     -
   Deschatelets Pascal Chief Scientific Officer   •       •      –    2022-02-10 4 D $47.12 $49,806 D/D (1,057) 893,650     -
   Watson David O. General Counsel   •       •      –    2022-02-10 4 D $47.12 $23,136 D/D (491) 132,444     -
   Brown Victoria L. Program Team Lead   •       •      –    2022-02-10 4 D $47.12 $8,246 D/D (175) 28,407     -
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-02-10 4 AS $50.00 $500,000 D/D (10,000) 53,179     -
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-02-10 4 OE $13.85 $138,500 D/D 10,000 63,179     -
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-02-10 4 D $47.12 $31,947 D/D (678) 53,179     -
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-02-08 4 AS $45.00 $450,000 D/D (10,000) 53,857     -
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-02-08 4 OE $13.85 $138,500 D/D 10,000 63,857     -
   Grossi Federico CHIEF MEDICAL OFFICER   •       •      –    2022-02-01 4 AS $40.58 $15,218 D/D (375) 103,566     -
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-01-31 4 AS $38.47 $47,434 D/D (1,233) 53,857     -
   Watson David O. General Counsel   •       •      –    2022-01-28 4 D $38.59 $25,084 D/D (650) 132,935     -
   Scheibler Lukas CHIEF INNOVATION OFFICER   •       •      –    2022-01-28 4 D $38.59 $24,775 D/D (642) 55,090     -
   Townsend Adam J. Chief Commercial Officer   •       •      –    2022-01-28 4 D $38.59 $30,872 D/D (800) 44,908     -
   Francois Cedric Chief Executive Officer   •       •      –    2022-01-28 4 D $38.59 $78,106 D/D (2,024) 1,338,463     -
   Sullivan Timothy Eugene Chief Financial Officer   •       •      –    2022-01-28 4 D $38.59 $25,084 D/D (650) 104,278     -
   Nicholson Nur Chief Technical Officer   •       •      –    2022-01-28 4 D $38.59 $25,084 D/D (650) 35,555     -
   Grossi Federico CHIEF MEDICAL OFFICER   •       •      –    2022-01-28 4 D $38.59 $25,084 D/D (650) 103,941     -
   Brown Victoria L. Program Team Lead   •       •      –    2022-01-28 4 D $38.59 $16,748 D/D (434) 28,582     -
   Eisele Jeffrey Exec VP, Program Team Lead   •       •      –    2022-01-28 4 D $38.59 $16,748 D/D (434) 32,989     -
  717 Records found
  Previous  10  11  12  13  14  15  16  17  18  19  Next   
  Page 17 of 29
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us